Browse PRG2

Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Bone marrow proteoglycan: Secreted. Note=The proform is secreted.; SUBCELLULAR LOCATION: Eosinophil granule major basic protein: Cytoplasmic vesicle, secretory vesicle. Note=The proform is secreted. The mature protein is found in the matrix of the eosinophil's large specific granule (crystalloid core).
Domain PF00059 Lectin C-type domain
Function

Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002215 defense response to nematode
GO:0032613 interleukin-10 production
GO:0032633 interleukin-4 production
GO:0032653 regulation of interleukin-10 production
GO:0032673 regulation of interleukin-4 production
GO:0032693 negative regulation of interleukin-10 production
GO:0032753 positive regulation of interleukin-4 production
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042742 defense response to bacterium
GO:0098542 defense response to other organism
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0030246 carbohydrate binding
GO:1901681 sulfur compound binding
Cellular Component GO:0030133 transport vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRG2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.6 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2480.475
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0510.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4040.422
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.4130.14
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.8380.255
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8550.596
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5810.361
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0740.937
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.3050.175
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3510.526
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3510.655
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5370.0139
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRG2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRG2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRG2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRG2
Nameproteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein)
Aliases BMPG; bone-marrow proteoglycan; eosinophil granule major basic protein; eosinophil major basic protein; natu ......
Chromosomal Location11q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRG2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRG2.
ID Name Drug Type Targets #Targets
DB00020SargramostimBiotechCSF2RA, CSF2RB, IL3RA, PRG2, SDC25